Talas, Raynelyn .
HRN: 23-18-44 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/06/2023
CEFUROXIME 500MG (TAB)
06/06/2023
06/13/2023
PO
500mg
BID
S/P NSVD With Episiorraphy
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes